- Optimi Health Corp. (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a subsidiary of Creso Pharma of Australia
- Halucenex is a Canada-based life sciences company researching novel, developing and licensing psychedelic compounds
- The supply agreement pertains to Optimi’s recently harvested first batch of psilocybe cubensis mushrooms
- The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies
- Optimi Health Corp opened trading at $0.23
Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.
Halucenex is a Canada-based life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.
Optimi has also confirmed that the supply agreement pertains to the entirety of the company’s recently harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility.
The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies.
“This first supply agreement, coming so soon after our first complete cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP psilocybin,” noted Bill Ciprick, CEO of Optimi.
“From this initial proof-of-concept batch, our cultivation team will continue to scale our operations to meet the demands of the sector, domestically and internationally with licensed entities and for individual patients within Canada according to the terms of the Special Access Program,” he added.
“Among our top priorities in the development of a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to secure a safe, consistent supply of GMP psilocybin,” stated Halucenex CEO, Bill Fleming.
Optimi Health Inc. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets.
Optimi Health Corp opened trading at $0.23.
